Oculus Innovative Sciences Introduces Two New Microcyn(R) Advanced Wound Care Products for U.S. Prescription Wound Care Market Jan 7, 2014
Oculus Innovative Sciences Receives Notification of Compliance With the Stockholders' Requirement of the NASDAQ Listing Rules Dec 30, 2013
Oculus Innovative Sciences Pays Off Debt to Strengthen Balance Sheet; Obtains $4.5 Million in Stockholders' Equity on a Pro Forma Basis as of September 30, 2013, Sufficient to Regain Compliance with NASDAQ Listing Rules Dec 19, 2013
Oculus Innovative Sciences Receives Mexican Ministry of Health Approval of Microcyn(R)-Based Hydrogel for Management of Scars Dec 12, 2013
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R) Scar Management HydroGel Dec 4, 2013
Oculus Innovative Sciences Reports Revenues of $4.1 Million for Second Quarter of Fiscal 2014, Meeting Guidance of Greater Than $3.6 Million Nov 19, 2013
Oculus Innovative Sciences Announces Fiscal Second Quarter 2014 Financial Results and Conference Call Nov 5, 2013
Oculus Innovative Sciences Reports Revenues of $3.4 Million for First Quarter of Fiscal 2014 Aug 8, 2013
Oculus Innovative Sciences Announces Fiscal First Quarter 2014 Financial Results and Conference Call Jul 31, 2013
